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Background: The aim of this work was to develop dry powder inhaler (DPI) formulations of salbutamol sulfate (SS)
by the aid of solid lipid microparticles (SLmPs), composed of biocompatible phospholipids or cholesterol.
Methods: The SLmPs were prepared by using two different solvent systems (ethanol and water-ethanol) and lipid
carriers (dipalmitoylphosphatidylcholine (DPPC) and cholesterol) with/without L-leucine in the spray drying process.
The spray-dried microparticles were physically-mixed with coarse lactose monohydrate in order to make our final
DPI formulations and were investigated in terms of physical characteristics as well as in vitro drug release profile
and aerosolization behavior.
Results: We observed significant differences in the sizes, morphologies, and in vitro pulmonary depositions between
the formulations. In particular, the SS-containing SLmPs prepared with water-ethanol (30:70 v/v) solution of DPPC and
L-leucine which had then been blended with coarse lactose (1:9 w/w) exhibited the highest emitted dose (87.9%) and
fine particle fraction (42.7%) among the formulations. In vitro drug release study indicated that despite of having a
significant initial burst release for both cholesterol and DPPC-based microparticles, the remained drug released more
slowly than the pure drug.
Conclusion: This study demonstrated the potential of using lipid carriers as well as L-leucine in DPI formulations of SS
to improve its aerosolization behavior and retard the release profile of the drug.
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L-leucineBackground
Local administration of drugs to the lungs presents several
advantages, especially, in patients with specific pulmonary
diseases, such as asthma, pulmonary infections or lung
cancer. The advantages include reduction in systemic side
effects, elevated drug concentration at the site of action,
and reduction in amount of drug administered to the
patient compared to traditional routs [1-3]. In this regard,
the area of particle engineering is becoming increasingly
attractive for the development of more efficient inhaled
therapeutics.* Correspondence: gilani@tums.ac.ir
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unless otherwise stated.One of the attractive applications of particle engineering
is to develop a sustained release (SR) formulation by using
suitable carriers, a kind of formulation that has not been
marketed yet, despite active research conducted on this
subject. A SR formulation will provide the active drug
over an extended duration of time, and therefore may
improve therapy by enhancing the compliance of the pa-
tients. In such formulations, it is expected that the overall
amount of drug and the side effects will be reduced [4-6].
However, the efforts for finding suitable, non-toxic excipi-
ents, which can produce a desired drug release profile and
improve the respirable fraction of the inhaled particles to
maximize drug deposition into smaller airways are
continuous and extensive.
One approach to SR delivery to the respiratory tract
utilizes liposomal formulations. Liposomes are promising
vehicles for pulmonary drug delivery owing to theirLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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toxicity of drugs after administration [7,8]. Several factors
such as the composition of lipids and the size of liposomes
can affect the performance of the system [9-11]. Many
studies have shown the applicability of liposomes in lung
delivery of a large variety of drugs such as cytotoxic
agents, anti-asthma drugs, antimicrobial agents, and drugs
for systemic action like insulin and other proteins [4,10].
However, there are some disadvantages about liposomal
vehicles that limits their application as commercial formu-
lations such as high production cost and instability during
storage even at low temperatures [12], and nebulization
[13,14] that can cause premature release of the entrapped
drug. The latter problem has been reported even about
the dry powder formulations prepared by jet milling
micronization of lyophilized liposomes, which deleteri-
ously affected their integrity [15].
Another approach for development of an inhalable SR
formulation is to produce solid lipid microparticles
(SLmPs). It has been suggested that SLmPs offer high
tolerability in the pulmonary tract, as they are mainly
made of biocompatible and biodegradable materials
[16,17]. Moreover, they possess several other advantages
compared to traditional vehicles such as polymeric drug
carriers, micelles or liposomes, including more physio-
chemical stability, incorporation of both lipophilic and
hydrophilic drugs, low large-scale production cost and
having no significant biotoxicity [16-19]. Phospholipids
and cholesterol have been previously used in inhalation
formulations as solid lipid carriers or fillers to improve
drug targeting to the lung. The prepared SLmPs presented
spherical shapes, reduced agglomeration tendency and
high fine particle fraction (FPF) [17,20].
Spray drying is an attractive solidification technique in
the field of respiratory drug delivery, with respect to its
relative simplicity, availability of large-scale equipment, cap-
ability to produce homogenous particle size distribution,
and ability to control various parameters that optimize the
particulate product characteristics such as size, size distri-
bution, shape, morphology and density [21-23]. Therefore,
it can be used as a suitable technology to produce dry pow-
der inhaler (DPI) products, which possess several advan-
tages over pressurized metered dose inhalers (pMDI), such
as being breath-activated and having no requirement of any
propellant [24].
Thus, the aim of this study was to design SLmPs using
cholesterol or dipalmitoylphosphatidylcholine (DPPC) by
spray drying method. The idea was emerged from the po-
tential ability of these excipients to entrap both water-
soluble and water-insoluble drugs, as well as providing a
prolonged local drug release [6,16]. Moreover, the safety
issue of these SLmPs over other vehicles was a key consid-
eration in our design process, since they are mainly made
from endogenous materials [25,26]. For this purpose, wechose to work with SS, a short acting beta2-adrenoceptor
stimulant with plasma half-life of 4–6 hours, which requires
frequent dosing for daily management of asthma. A SR
preparation of this agent is desirable approach to improve
therapy of asthma, especially in non-compliant patients and
also for covering the nocturnal decline of the drug [27],
when administered at the bed time.
Aside from SR properties, an effective DPI formulation
should offer optimum particle characteristics to achieve
high FPF and reduce the central deposition in pulmonary
airways. In other words, a suitable DPI formulation should
have the ability to reach deep lung regions and disperse
adequately within the airflow of the patient. Indeed, de-
creasing of both particle size and density can be achieved
by spray drying technique in order to generate particles
with satisfactory respirable fraction [23]. However, the
dispersibility of the particles is another factor that has to
be taken into consideration. The particle aggregation asso-
ciated with cohesive forces between them can be regulated
using excipients such as coarse crystalline lactose, which
is currently serving as the drug carrier and also the bulk-
ing agent in most available DPI products [23]. Usually,
drug particles and such excipients are combined in a phys-
ical blending process during which the microparticles are
attached to the surface of the carrier. Therefore, our final
DPI formulations consisted of physically-mixed SLmPs
with large coarse lactose carrier particles. To aid dispersi-
bility, it has been also proven that co-spray drying of
simple amino acids, especially the hydrophobic ones such
as L-leucine, can improve dispersion of the powder and
may enhance the fraction of respirable particles [28]. Thus,
we used this amino acid in our spray drying process to
evaluate its effects on the aerodynamic performance of the
resultant DPI formulation.
In the present study, the obtained SLmPs were further
characterized for their physical properties, in vitro aerosol-




SS was supplied as micronized powder from Darupakhsh
(Iran). Cholesterol was purchased from Merck (Germany),
and the phospholipid, DPPC, was supplied from Lipoid
(Germany). Inhalation grade lactose (Pharmatose 325 M)
with D50% of about 60 μm was obtained from DMV
Internationals (The Netherlands). Other chemical reagents
and solvents including the HPLC grade ones were pur-
chased from either Merck or Sigma. L-Leucine was also
supplied from Merck (Germany).
Preparation of the lipid-based microparticles
The SLmPs were prepared, at laboratory scale, by spray
drying method using a Büchi Minispray dryer B-191-a
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study, we decided to improve the drying efficiency of the
lipid excipients by using a jacketed cyclone with cold-
water circulation, to cool down the cyclone separator wall
and thus decrease the lipid particles’ adhesion and
agglomeration.
Two different types of formulations were spray dried for
the preparation of SLmPs. The first type was prepared by
dispersing the SS microparticles within an ethanol solu-
tion of the hydrophobic excipients, cholesterol or DPPC.
The suspensions were sonicated for 10 min before spray
drying to ensure the adequate dispersion of the drug. The
second type of formulations was obtained from spray dry-
ing of water-ethanol (30:70 v/v) solution of the drug and
the lipid materials. Details are shown in Table 1.
The spray drying conditions were as following: Solid con-
tent, 5% w/v; Nozzle size, 0.5 mm; Inlet temperature, 80/
100°C (depending on the solvent system); Outlet tempera-
ture, 54/65°C (depending on the inlet temperature); Spray-
ing air flow rate, 800 L/h; Feed rate, 0.2 g/min; Cold water
circulation in the jacketed cyclone, 0°C.
Furthermore, as shown in Table 1, L-leucine was co-
spray dried at the amount of 10% w/w with respect to the
solid content with water-ethanol solution of DPPC and SS.
Finally, all the obtained formulations were physically
blended with inhalation grade lactose monohydrate (Phar-
matose® 325 M) at a ratio of 1:9 w/w in a Turbula mixer
from Dorsa Novin (Iran) for 60 min at a low speed
(46 rpm).
Determination of SS content
Quantification of CIP was conducted by HPLC using a
mobile phase consisting of water, methanol and phosphate
buffer (pH 2.8) in the ratio of 60:20:20 at a flow rate of
1 mL/min. The phosphate buffer was prepared by dissolv-
ing 2.625 g ammonium phosphate in 50 mL purified de-
ionized water, adding 2.8 mL of phosphoric acid (85%)
and diluting to 100 mL with purified deionized water. The
HPLC system consisted of a pump (Waters 600E, Millipore,
USA), a C18 Tracer Excel column (15 × 0.46 cm, 5 μm,
Spain) and a UV detector (Waters 486, USA) at 276 nm.
Bamethan sulfate (to final concentration of 10 μg/mL) wasTable 1 Composition of different spray-dried formulations







7 37.5 DPPC + Le
*Percentage of the total solid content (w/w).added as the internal standard to each sample just before
analysis. From the relative area under the peak, linearity
(R2 = 0.999) was achieved using standard aqueous solutions
of SS between 0.5 and 50 μg/mL.
For all the prepared DPI formulations, the content uni-
formity was evaluated by taking 10 random samples, each
weighing 10 mg powder which were subjected to lipid
extraction by adding 1.5 mL chloroform to each one and
centrifugation at 37565 × g for 20 min. The recovered
drug was diluted with mobile phase before being subjected
to HPLC analysis. Mixtures with relative standard devi-
ation values of less than 10%, as recommended by The
United States Pharmacopeia, were considered to be satis-
factorily mixed.
Particle size measurement
The size distribution of the microparticles was determined
by laser diffraction method using Malvern Mastersizer X
(UK) after the formulations had been dispersed in appro-
priate medium (saturated solution of SS in water) and
sonicated for 2 min. The geometrical diameter was
expressed as volume median diameter (D50%). Also the
Span values of formulations were defined as D90%−D10%D50% ,
which represents the breadth of the particle distribution.
Each measurement was repeated in triplicate.
Scanning electron microscopy
Particle morphology was observed by scanning electron
microscopy (SEM) using Philips XL30 equipment (The
Netherlands). The samples were coated with gold under
relative vacuum by means of Bal-Tec/SCDOOS sputter
coater (Switzerland) and were examined under an accel-
erating voltage of 25 kv.
Determination of true density
The density was assessed with Quantachrome helium pyc-
nometer (USA). The basis of this method is on putting the
sample of known mass into a cell of known volume.
Briefly, when helium penetrates into the cell at a vacuum,
it occupies the entire volume of the cell, so the actual
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were accurately calculated. Each sample was analyzed
thrice.
Aerosol performance of SLmPs
The in vitro pulmonary deposition of the powders was de-
termined by Twin Stage Impinger (TSI) glass apparatus
from Copley Scientific (UK). A dry powder formulation
device, Novartis Cyclohaler® (Switzerland), was filled with
a hard gelatin capsule loaded with 10 mg of each formula-
tion. On the other hand, the mobile phase was introduced
to stage 1 (7 mL) and stage 2 (30 mL) of the TSI. Once
the assembly had been checked to be tight and vertical,
the Cyclohaler® had been inserted to the rubber mouth-
piece attached to the throat part of the impinger. The test
was operated at 60 L/min for 4 s. The flow rate was
achieved using a rotary vein pump from Copley Scientific
(UK). After the operation, the impinger components had
been washed into separate volumetrics (25 mL for the
throat and stage 1, and 50 mL for the device and stage 2)
with the same solution. Their contents were assayed for
SS, after the lipid had been extracted with certain ratio of
chloroform.
Fine particle dose (FPD) was considered as the amount
of drug deposited in stage 2 (dae < 6.4 μm). The emitted
dose (ED) was determined as a percent of total powder
exiting the capsule and the device. The FPF was calculated
as the percent of the ratio of FPD to the total amount of
drug emitted per capsule.
Determination of drug release from SLmPs
Since the volume of surface liquid in the respiratory tract
is relatively low, the conventional European Pharmacopeia
methods cannot be used for exact evaluation of dissol-
ution behavior of inhaled drugs due to their large volumes
of dissolution media (900–1000 mL) [29]. Hence we used
a dispersion method to measure in vitro release of the
drug from SLmPs. Briefly, 10 mg of each formulation was
suspended individually in 10 mL phosphate buffered salineTable 2 Particle size measurement obtained by laser diffracti







7 37.5 DPPC + Leucine
C1 100 -
C2 100 -
*Percentage of the total solid content (w/w).(PBS, PH = 7.4) in test tubes and incubated in a shaker
(Grant instruments, Cambridge, England) at 37°C on
50 rpm. At certain time intervals of 0.25, 0.5, 1, 2, 4, 8,
and 12 hours, three tubes were picked and individually
assayed for SS after being filtered. The mean value of the
tree tubes for each time interval was calculated, and plot-
ted as cumulative amount of SS released over 12 hours.
Statistical analysis
Data for all measurements were considered as the mean ±
standard deviation (SD) of at least three separate experi-
ments. One-way analysis of variance (ANOVA) test was
used for statistical comparison of the results while p < 0.05
was considered significant in all cases.
Results and discussion
Different powder compositions were formulated using
the spray drying technique, with the aim of studying the
influence of lipid composition and the solvent type on
the physiochemical properties and the aerosolization be-
havior of the powders. Table 1 gives an overview of all
the prepared powder formulations. It should be men-
tioned that the content uniformity test was conducted
for both spray-dried formulations and the physical
blends, using a conventional invasive sampling method.
The active drug content was quantified by HPLC, and
ranged between 95 ± 2% and 103 ± 3% for different
formulations.
Evaluation of physiochemical properties of aerosol
particles
The particle size characteristics of the formulations are
summarized in Table 2. The results showed that for the
same lipid and solvent composition of the formulations
(cholesterol in ethanol), the percentage of SS in the sus-
pensions used for spray drying had no significant effect on
the size of resultant SLmPs (p > 0.05). Additionally, the
D50% of the spray dried formulations obtained from etha-
nol suspension of the drug were shown to be dependenton method (mean ± SD)
Solvent system Inlet temp. (°C) D50% Span
Ethanol 80 3.23 ± 0.48 3.19
Ethanol 80 5.04 ± 0.66 1.75
Ethanol 80 4.16 ± 0.32 1.66
Ethanol 80 1.42 ± 0.15 0.87
Water-Ethanol 100 7.32 ± 0.28 2.26
Water-Ethanol 100 4.02 ± 0.18 2.54
Water-Ethanol 100 4.04 ± 0.25 2.23
Ethanol 80 3.70 ± 0.13 2.47
Water-Ethanol 100 5.83 ± 0.21 1.82
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for DPPC-based microparticles than cholesterol (p < 0.05).
Changing the solvent from ethanol to water-ethanol
(30:70 v/v) resulted in an increase in D50% values of both
DPPC and cholesterol-based particles (p < 0.05). It seems
that the enhancement in the inlet temperature of spray
drying process has contributed to the particle size enlarge-
ment, as it was previously proven that adding in tempe
rature will lead to increase in the diameter of particles
[30,31]. Furthermore, the laser diffraction particle size ana-
lysis showed that co-spray drying of L-leucine with DPPC
and SS did not significantly change the particle size distri-
bution with respect to the counterpart sample without L-
leucine (p > 0.05).
Scanning electron microphotographs of the SLmPs are
shown in Figure 1. As shown in Figure 1a-c, changing the
solvent in the feed solution did not seriously change the
spherical shape of cholesterol-based SLmPs which is typic-
ally obtained via spray drying technique [32]. Processing
of the drug and DPPC in ethanol produced particles simi-
lar to that of cholesterol-based samples (Figure 1d). How-
ever, as it is indicated in Figure 1e, applying a mixed
solution of water-ethanol (30:70 v/v) in formulations con-
sisted of DPPC resulted in production of wrinkled parti-
cles which used to be mostly spherical when pure ethanol
was applied as the solvent. It is supposed that the solubil-
ity saturation of the formulation components upon former
evaporation of the more volatile solvent (ethanol) leads to
formation of a primary solid shell which then collapses as
the core’s water content evaporates [33]. In this case, the
surface-active DPPC could have contributed to the forma-
tion of this primary solid shell during particle formation
stage. Incorporation of L-leucine within this formulation
led the spherical shape back to the particles, as it is clearly
shown in Figure 1f. It seems that the more tendency of
L-leucine to water than ethanol and its subsequent
localization in the core of the primary particles inhibitedFigure 1 Scanning electron micrographs of SLmPs containing salbuta
F6, f) F7.the shell to completely collapse after water evaporation.
Figure 2 shows the attachment of SLmPs obtained from
water-ethanol (30:70 v/v) solution of DPPC and SS to the
large lactose surface. In fact, physical blending of the for-
mulations with lactose monohydrate as the coarse carrier
promoted the adhesion of SLmPs onto its surface. This
process was expected to aid the deaggregation and disper-
sion of particles within the respiratory flow [34].
The true density values of the spray dried samples
obtained by helium pycnometry are shown in Table 3.
SS powders, which were spray dried from both kinds of
the solvent systems, were used as controls. The results
suggested that utilizing the lipid components along with
the drug could result in reduction of the true density of
the spray-dried powders. Actually, particle’s aerodynamic
diameter (da) is a function of particle’s geometric diameter
(d), density (ρ) and morphology (χ, shape factor) accord-
ing to the following equation:
da ¼ d√ ρ=χð Þ
In other words, particles with low density have smaller
aerodynamic diameter than their geometric diameter.
Thus, it can be of great value to reduce the density and
affect the aerodynamic diameter of the particles by chan-
ging a DPI formulation composition. In this regard, Scalia
et al. had previously reported the true density values of
lower than 1 g cm−3 for the lipid microparticles obtained
by melt emulsification technique [35].
Aerosol performance of the SLmPs
Table 4 shows the ED (%), FPD (μg) and FPF (%) values
of the spray dried SLmPs (formulations number 1 to 7)
along with the same powders mixed with lactose carrier
in the ratio of 1:9 w/w (formulations number 8 to 12).
The aerodynamic characteristics were measured using a
TSI at the flow rate of 60 L/min after aerosolization bymol sulfate in different formulations: a) F2, b) F3, c) F5, d) F4, e)
Figure 2 Scanning electron micrographs of SLmPs blended with lactose. a) magnification ×240, b) more magnification (×5000) representing
SLmPs deposited on the surface of lactose carriers.
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the inhaler and the different parts of the TSI ranged
between 90.1-95.2% of the total loaded drug.
It seems that the type of solvent system and lipid ex-
cipients had a direct effect on aerosolization properties
of the powders. Among the formulations prepared by
cholesterol and ethanol, increasing the drug content
from 12.5% to 25% did not make a significant change on
FPF values (P > 0.05), but the initial drug content of
37.5% (Formulation No. 3) appeared to have higher FPF
(%) than the others (P < 0.05). However, changing the
type of cholesterol solvent to 30:70 v/v water-ethanol
(Formulation No. 5) resulted in FPF reduction which
seems to be due to particle size enlargement of the
resultant SLmPs [36,37]. The difference between FPF
values associated with the type of solvent was more
noticeable when DPPC was used as the lipid excipient.
The consequence of changing the solvent from pure
ethanol to 30:70 v/v water-ethanol was a noticeable
increase in FPF values from 4.1% to 22.5% for DPPC-
based formulations (P < 0.05). The latter results are not
in accordance with the particle size determinations ob-
tained by laser diffraction, since the formulation pre-
pared by the aid of ethanol solution of DPPC had
smaller size than that of water-ethanol solution of it. In
this case, the particle aggregation of very small particles
(D50% =1.42 μm) made up of DPPC as the lipid excipient
and ethanol as the solvent, seemed to be the main cause
of owning the lowest FPF value. In addition, wrinkled par-
ticles usually improve the respirable fraction of a DPITable 3 True density values obtained by the helium pycnome







*Percentage of the total solid content (w/w).formulation by decreasing the interparticulate cohesion
forces as well as enhancing the powder dispersibility [38].
The incorporation of L-leucine to the formulation num-
ber 6 which was prepared from 30:70 v/v water-ethanol
solution of DPPC and SS resulted in insignificant FPF im-
provement (P > 0.05). As mentioned earlier, both kinds of
formulations (F6 and F7) had almost similar particle aver-
age diameters, but different shapes. Although L-leucine
plays a role of anti-adherent amino acid that can improve
the deagglomeration of SLmPs [29], it seems that the cor-
rugated particles made from spray-dried SS and DPPC
could compensate the absence of L-leucine and act as
favorably as the spherical particles of F7 in the in vitro
pulmonary deposition test.
Moreover, simple blending of micron-sized SLmPs with
coarse lactose monohydrate terminated in noticeable FPF
elevation, compared to the FPF values of uncombined
SLmPs. It seems that the absorption of the SLmPs to the
surface of lactose, and the subsequent improvement in the
dispersibility and deaggregation of them within the airflow
resulted in elevated drug deposition in stage 2 of the TSI
[24,34]. Finally, we found that co spray-dried DPPC/L-leu-
cine, which had then been blended with coarse lactose (in
the ratio of 1:9 w/w), was the most appropriate formula-
tion for SS in term of aerosol performance.
In vitro drug release study
The release profiles of SS from SLmPs are reported in
Figure 3. It should be noted that release of pure micron-
ized SS was rapid as nearly all the amount of the drug waster
tem Inlet temp. (°C) Density (g/cm3)
80 1.11 ± 0.09
nol 100 1.15 ± 0.10
80 1.15 ± 0.08
nol 100 1.18 ± 0.07
80 1.33 ± 0.11
nol 100 1.41 ± o.12
Table 4 Fine particle dose (FPD), emitted dose (ED) and fine particle fraction (FPF) of salbutamol sulfate after
aerosolization from different formulations (mean ± SD)
Formulation number Lipid excipients Solvent system** Inlet temp.(°C) Blending excipient** FPF(%) FPD(μg) ED(%)
1 Cholesterol E 80 - 16.7 ± 0.8 165 ± 4.4 79.2 ± 2.1
2 Cholesterol E 80 - 16.5 ± 1.2 305 ± 5.7 74.1 ± 2.5
3 Cholesterol E 80 - 21.1 ± 0.9 575 ± 7.3 74.8 ± 1.8
4 DPPC E 80 - 4.1 ± 0.3 138 ± 3.2 89.3 ± 1.6
5 Cholesterol W/E 100 - 12.1 ± 0.7 310 ± 4.8 69.1 ± 2.1
6 DPPC W/E 100 - 22.5 ± 1.3 686 ± 7.5 81.1 ± 2.3
7 DPPC + leucine W/E 100 - 23.7 ± 1.1 712 ± 6.9 80.2 ± 1.9
8 Cholesterol E 80 Lac. 24.1 ± 1.4 75 ± 3.1 82.6 ± 2.5
9 Cholesterol W/E 100 Lac. 20.3 ± 0.8 61 ± 3.5 80.1 ± 2.2
10 DPPC E 80 Lac. 16.6 ± 0.9 50 ± 2.8 80.1 ± 1.6
11 DPPC W/E 100 Lac. 33.7 ± 1.5 108 ± 3.7 85.3 ± 2.7
12 DPPC + leucine W/E 100 Lac. 42.7 ± 1.7 141 ± 4.1 87.9 ± 2.3
C1
* - E 80 Lac. 17.6 ± 1.0 146 ± 2.8 83.4 ± 1.9
C2
* - W/E 100 Lac. 14.4 ± 0.8 116 ± 2.2 81.1 ± 2.1
*C1 and C2 are control formulations of 5% (w/v) salbutamol sulfate in spray drying solution.
**E stands for Ethanol, W for Water, and Lac for lactose.
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other studies [35]. In this study, generating inhalable
microspheres from SS, cholesterol and ethanol provided a
SR profile of the drug. In this regard, several other studies
had shown the usefulness of SLmPs in developing SR
formulations [7,17,18]. As shown in Figure 3, the release
profile of SS from SLmPs produced from cholesterol and
ethanol exhibited a burst release of approximately 50%,
followed by a sustained SS release pattern over 12 hours,
whilst in cholesterol-based SLmPs obtained from water-
ethanol solution of SS, no SR profile was observed. This
observation can be explained by the fact that the drug has
a hydrophilic and ionized nature and does not dissolve in
ethanol, so upon application of water and ethanol as the
mixed solvent system, the drug mainly partitions into the
water phase during the particle formation stage in spray
drying chamber, and thus accumulates on the surface ofFigure 3 In vitro release profile of salbutamol sulfate from
different formulations.the particle as the water evaporates. However, when the
ethanol suspension of the drug is used, it is more likely for
SS to be entrapped within the core of SLmPs as it does not
dissolve in ethanol and thus does not migrate to lipid sur-
face of the generating microparticles. In contrast, DPPC-
based microparticles from ethanol suspension of SS did
not show any SR profile, while changing the feed solv-
ent from ethanol to water-ethanol (30:70 v/v) improved
the drug entrapment within these DPPC-based SLmPs
and exhibited a SR profile over 12 hours with a burst
release of nearly 35%. In fact, besides the effect of the
solvent, the affinity between the drug and lipid material
is another efficient factor, which determines the reten-
tion capacity of SLmPs [17]. Herein, DPPC tends to
place at the surface of the particles while the drug
mostly remains within the aqueous core of the primary
particles in the drying chamber before all the water
content is subjected to evaporation. Thus, it is possible
for DPPC to serve as a SS-retarding carrier in the men-
tioned inhalable formulation.
It worth mentioning that, this kind of SR pattern
should be justified according to the dissolution rate of
the pure drug powder as well as its specific pulmonary
delivery rout. In this regard, it can be an acceptable SR
pattern for SS DPI formulation since the lung retention
time of microparticles is dependent on the generation
number of the airway where the inhaled particles are de-
posited, and our SLmPs showed high FPF indicating that
they have the potential to sufficiently penetrate deep into
the lungs and avoid mucociliary clearance in the con-
ducting airways. So the prolonged duration of the effect
of SS can be expected by the aid of these SLmPs.
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The type of lipid, presence of L-leucine in the feed solu-
tion, and the solvent system from which the SS-containing
SLmPs were spray dried were the factors, which greatly
affected the particle morphologies and aerosolization prop-
erties. We also observed substantial effects that physical
mixing of spray-dried microparticles with coarse carrier
can have on the aerosol performance. Among different
DPI formulations, powders spray dried from water-ethanol
solution of the drug, DPPC and L-leucine which were also
physically blended with coarse lactose exhibited the best
aerosolization properties. Despite having noticeable
burst release during the first hour of the study, some
SS-containing SLmPs showed significant release retard-
ation compared the pure drug. The present study sug-
gests that DPPC and L-leucine can be interesting
additives for further developments of SS inhalable pow-
der formulations.
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